We are live on !
Find out more
Superstring Capital Management Portfolio holdings
AUM
$158M
Turnover
44.19%
1-Year Est. Return
418.32%
This Fund
S&P 500
This Quarter Est. Return
+14.89%
1 Year Est. Return
+418.32%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$84.5M
AUM Growth
+$408K
(+0.49%)
Cap. Flow
-$10.2M
Cap. Flow % of AUM
Cap. Flow %
-12.08%
Top 10 Holdings %
Top 10 Hldgs %
59.13%
Holding
48
New
14
Increased
9
Reduced
9
Closed
12
Avg Time Held
Equity + Options
0.5
years
Top 10 Avg Time Held
Equity + Options
0.5
years
Top 20 Avg Time Held
Equity + Options
0.4
years
Avg Time Held Equity only
0.5
years
Top 10 Avg Time Held Equity only
0.5
years
Top 20 Avg Time Held Equity only
0.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$4.79M |
| 2 |
Ultragenyx Pharmaceutical
RARE
|
+$4.7M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$4.66M |
| 4 |
Ionis Pharmaceuticals
IONS
|
+$3.22M |
| 5 |
Bicara Therapeutics
BCAX
|
+$2.26M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Legend Biotech
LEGN
|
+$5.44M |
| 2 |
Zai Lab
ZLAB
|
+$5.26M |
| 3 |
Pfizer
PFE
|
+$4.97M |
| 4 |
UroGen Pharma
URGN
|
+$3.22M |
| 5 |
Oric Pharmaceuticals
ORIC
|
+$3.18M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.04% |
| 2 | Miscellaneous | 4.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Cogent Biosciences
COGT
$5.13B
| $6.91M | 8.19% |
962,951
+188,230
| +24% | +$1.04M |
2024 Q4
2 quarters
|
|
|
VRNA
2
DELISTED
Verona Pharma
VRNA
| $6.52M | 7.73% |
68,982
-27,839
| -29% | -$2.06M |
2025 Q1
1 quarter
|
|
|
3
Neurocrine Biosciences
NBIX
$16.2B
| $5.1M | 6.04% |
+40,608
| New | +$4.66M |
2025 Q2
0 quarters
|
|
4
DELISTED
Terns Pharmaceuticals
TERN
| $4.8M | 5.68% |
1,286,681
-70,472
| -5% | -$220K |
2024 Q2
4 quarters
|
|
|
5
Ultragenyx Pharmaceutical
RARE
$1.54B
| $4.74M | 5.61% |
+130,422
| New | +$4.7M |
2025 Q2
0 quarters
|
|
|
6
Zai Lab
ZLAB
$2.81B
| $4.72M | 5.59% |
134,895
-160,052
| -54% | -$5.26M |
2024 Q2
4 quarters
|
|
|
7
Jazz Pharmaceuticals
JAZZ
$14.8B
| $4.68M | 5.54% |
+44,107
| New | +$4.79M |
2025 Q2
0 quarters
|
|
8
PUT
DELISTED
Soleno Therapeutics
SLNO
| $4.19M | 4.96% |
+50,000
| New | +$3.74M |
2025 Q2
0 quarters
|
|
9
BridgeBio Pharma
BBIO
$14.5B
| $4.18M | 4.95% |
96,766
-87,156
| -47% | -$3.17M |
2023 Q4
6 quarters
|
|
10
Travere Therapeutics
TVTX
$4.61B
| $4.09M | 4.84% |
276,474
+38,987
| +16% | +$646K |
2025 Q1
1 quarter
|
|
|
11
Ionis Pharmaceuticals
IONS
$6.45B
| $3.88M | 4.6% |
+98,267
| New | +$3.22M |
2025 Q2
0 quarters
|
|
|
12
Oric Pharmaceuticals
ORIC
$880M
| $3.5M | 4.15% |
344,922
-474,272
| -58% | -$3.18M |
2024 Q3
3 quarters
|
|
|
13
DELISTED
Soleno Therapeutics
SLNO
| $2.82M | 3.34% |
33,691
+14,359
| +74% | +$1.07M |
2025 Q1
1 quarter
|
|
14
Savara
SVRA
$900M
| $2.54M | 3.01% |
1,115,379
+149,176
| +15% | +$406K |
2023 Q4
6 quarters
|
|
15
DELISTED
89bio
ETNB
| $2.09M | 2.47% |
212,377
+103,221
| +95% | +$855K |
2023 Q4
6 quarters
|
|
16
Cytokinetics
CYTK
$7.72B
| $2.02M | 2.39% |
61,103
-11,889
| -16% | -$414K |
2023 Q4
6 quarters
|
|
|
17
Bicara Therapeutics
BCAX
$542M
| $1.76M | 2.09% |
+189,699
| New | +$2.26M |
2025 Q2
0 quarters
|
|
18
Cabaletta Bio
CABA
$217M
| $1.61M | 1.91% |
1,060,764
+601,792
| +131% | +$938K |
2024 Q1
5 quarters
|
|
19
Tectonic Therapeutic
TECX
$380M
| $1.57M | 1.86% |
79,058
+28,312
| +56% | +$574K |
2025 Q1
1 quarter
|
|
20
Insmed
INSM
$23.9B
| $1.47M | 1.74% |
+14,571
| New | +$1.11M |
2025 Q2
0 quarters
|
|
21
United Therapeutics
UTHR
$24.3B
| $1.4M | 1.66% |
+4,874
| New | +$1.46M |
2025 Q2
0 quarters
|
|
|
RNAM
22
DELISTED
Avidity Biosciences
RNAM
| $1.34M | 1.58% |
47,037
+24,766
| +111% | +$738K |
2025 Q1
1 quarter
|
|
|
23
UroGen Pharma
URGN
$1.26B
| $1.2M | 1.43% |
87,912
-335,720
| -79% | -$3.22M |
2024 Q4
2 quarters
|
|
24
Protara Therapeutics
TARA
$126M
| $1.09M | 1.29% |
360,000
| – | – |
2024 Q4
2 quarters
|
|
25
Zenas BioPharma
ZBIO
$1.69B
| $1.08M | 1.28% |
111,605
| – | – |
2024 Q3
3 quarters
|
|
Similar funds
MA
Superstring Capital Management's Q2 2025 Portfolio in Review
As of Q2 2025, Superstring Capital Management held 48 positions worth $84.5M, up 0.49% from $84M the previous quarter. Its ten largest holdings account for 59% of the portfolio.
Superstring Capital Management withdrew a net $10.2M in Q2 2025, closing 12 positions and reducing 9 holdings. Its most notable exit was Legend Biotech, an estimated $5.44M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
Against the trend, Superstring Capital Management opened a new position in Jazz Pharmaceuticals worth $4.68M.
- Superstring Capital Management's largest Q2 2025 buy was Jazz Pharmaceuticals: 44,107 shares worth $4.68M.
- Superstring Capital Management added most to Soleno Therapeutics in Q2 2025, an estimated $1.07M increase.
- Superstring Capital Management's biggest Q2 2025 reduction was Zai Lab, cutting an estimated $5.26M.
- Superstring Capital Management fully exited Legend Biotech in Q2 2025, selling an estimated $5.44M.
- Superstring Capital Management's ten largest holdings make up 59% of its $84.5M portfolio in Q2 2025.
- Superstring Capital Management opened 14 new positions and closed 12 in Q2 2025.
- Superstring Capital Management's portfolio value rose 0.49% quarter-over-quarter to $84.5M.
Based on Superstring Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.